* XOMA Royalty Corp XOMA.OQ reported quarterly adjusted
earnings
of 84 cents per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of -45 cents. The mean expectation of three analysts for the
quarter was for a loss of 27 cents per share. Wall Street
expected results to range from -56 cents to -1 cents per share.
* Revenue rose 241% to $5.65 million from a year ago;
analysts
expected $8.38 million.
* XOMA Royalty Corp shares had fallen by 2.4% this
quarter and
gained 25.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 48.6%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for XOMA Royalty Corp
is $42.00
This summary was machine generated from LSEG data August 13 at
12:29 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -0.27 0.84 Beat
Mar. 31 2024 -0.81 -0.86 Missed
Dec. 31 2023 -0.36 -0.49 Missed
Sep. 30 2023 -0.48 -0.60 Missed